<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16043733
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     07
    </month>
    <day>
     26
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2005
    </year>
    <month>
     10
    </month>
    <day>
     04
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0149-5992
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       28
      </volume>
      <issue>
       8
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Aug
       </month>
      </pubdate>
     </journalissue>
     <title>
      Diabetes care
     </title>
     <isoabbreviation>
      Diabetes Care
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      1922-8
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Effective type 2 diabetes management requires prompt intervention if glycemic control is not achieved by nonpharmacological means. This study investigates whether inhaled insulin (INH; Exubera) can achieve target glycemic control in patients failing on diet and exercise.
     </abstracttext>
     <abstracttext label="RESEARCH DESIGN AND METHODS" nlmcategory="METHODS">
      Patients with suboptimal control on diet and exercise (HbA(1c) [A1C] 8-11%) were randomized to 3 months' treatment with either INH before meals (n = 76) or rosiglitazone 4 mg twice a day (n = 69), in conjunction with a diet and exercise regimen. The primary end point was percentage of patients achieving A1C &lt;8.0%.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The INH and rosiglitazone groups had comparable baseline A1C values (9.5 vs. 9.4%, respectively). Significantly more patients achieved A1C &lt;8.0% (83 vs. 58%, adjusted odds ratio 7.14 [95% CI 2.48-20.58], P = 0.0003), A1C &lt;7.0% (44 vs. 18%, 4.43 [1.94-10.12]), and A1C &lt; or = 6.5% (28 vs. 7.5% 5.34 [1.83-15.57]) with INH. A1C decrease was greater with INH (-2.3% vs. -1.4%, adjusted treatment group difference: -0.89% [95% CI -1.23 to -0.55]) with final mean A1C values of 7.2 and 8.0% for INH and rosiglitazone, respectively. Hypoglycemia (episodes per subject-month) was higher with INH (0.7 vs. 0.05, risk ratio 14.72 [95% CI 7.51-28.83]), with no severe hypoglycemic episodes. Pulmonary function changes were small and comparable between groups.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      INH could be an effective therapy for people with type 2 diabetes early in the course of their disease.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Texas Health Science Center, Diabetes Division, 7703 Floyd Curl Dr., San Antonio, TX 78284, USA. albarado@uthscsa.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       DeFronzo
      </lastname>
      <forename>
       Ralph A
      </forename>
      <initials>
       RA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bergenstal
      </lastname>
      <forename>
       Richard M
      </forename>
      <initials>
       RM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cefalu
      </lastname>
      <forename>
       William T
      </forename>
      <initials>
       WT
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pullman
      </lastname>
      <forename>
       John
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lerman
      </lastname>
      <forename>
       Sam
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bode
      </lastname>
      <forename>
       Bruce W
      </forename>
      <initials>
       BW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Phillips
      </lastname>
      <forename>
       Lawrence S
      </forename>
      <initials>
       LS
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       Exubera Phase III Study Group
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Clinical Trial, Phase III
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Diabetes Care
    </medlineta>
    <nlmuniqueid>
     7805975
    </nlmuniqueid>
    <issnlinking>
     0149-5992
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hemoglobin A, Glycosylated
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hypoglycemic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazolidinediones
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      11061-68-0
     </registrynumber>
     <nameofsubstance>
      Insulin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      122320-73-4
     </registrynumber>
     <nameofsubstance>
      rosiglitazone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Inhalation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetic Diet
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Exercise
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hemoglobin A, Glycosylated
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Insulin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Selection
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Research Design
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thiazolidinediones
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      7
     </month>
     <day>
      27
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2005
     </year>
     <month>
      10
     </month>
     <day>
      5
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      7
     </month>
     <day>
      27
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     28/8/1922
    </articleid>
    <articleid idtype="pubmed">
     16043733
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

